Alzheimer’s disease is a slow and progressive neurodegenerative disorder resulting from the accumulation of amyloid beta protein around neurons resulting in progressive loss of memory and disordered cognitive functions. We reviewed multiple previous studies on Lecanemab and observed that phase 3 clinical trials showed the potential of the drug Lecanemab in the treatment of Alzheimer’s disease. Lecanemab targets amyloid beta and reduces its accumulation around neurons resulting in slowing down the progression of the disease. But this drug is also related to its adverse events so longer studies needed to determine its safety and efficacy.